SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
NexStar Pharm(NXTR)
An SI Board Since December 1996
Posts SubjectMarks Bans Symbol
328 5 0 NXTR
Emcee:  Miljenko Zuanic Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
78 I do not know the answer to your trading questions. I think the reason the stocBill Tomko-3/4/1997
77 Miljenko, facts are pretty much as I laid them out in my original note (I confiWWS-3/3/1997
76 Bill, I do not have access to WSJ on-line. Can you trim article and post on thrMiljenko Zuanic-3/3/1997
75 Sorry, I misspelled the product; it should have been DaunoXome!WWS-3/3/1997
74 Miljenko, problem (as reported in on-line WSJ) is that FDA issued an official &WWS-3/3/1997
73 Today weakness can be related to announcement that LIPO's Abelcet is approvMiljenko Zuanic-3/3/1997
72 Bill, I am not good in technical analysis. Today I check min. charts for NXTR (Miljenko Zuanic-3/3/1997
71 Today weakness can be related partially to overall week market and probably to Miljenko Zuanic-2/26/1997
70 Have you seen any news to account for the vol. and price weakness?Bill Tomko-2/26/1997
69 Recent news. Three prominent brokerages house in Feb. recommended NXTR as Bay; Miljenko Zuanic-2/25/1997
68 So quiet. Everyone looking for Europe patent litigation news! Today news on SchMiljenko Zuanic-2/20/1997
67 I don't know much about Repligen's approach. VEGF antagonists look mostLothar S.-2/17/1997
66 Hi Lothar, I assume that you have knowledge on angiogenesis after you drooped RMiljenko Zuanic-2/16/1997
65 Is Repligen really broke? I am glad that I did not buy, which I was consideringLothar S.-2/15/1997
64 short answer is I don't know. I did not htink that they were talking about Bill Tomko-2/13/1997
63 Watch out for any company chasing the angiogenesis rainbow. I owned some stock Jim Folts-2/12/1997
62 Bill, I think that we have very similar idea. Last week I was doing deep researMiljenko Zuanic-2/12/1997
61 I have not forgotten you, I've just been up to my eyes in projects. I have Bill Tomko-2/12/1997
60 There is why? NXTR: Major Broker decreased estimate for fiscal year enMiljenko Zuanic-2/9/1997
59 just to let you guys know that first call recently dropped estimates for the deChander Arora-2/8/1997
58 LIPO Earning reports is only indication for liposomal amphotericin B market potMiljenko Zuanic-2/6/1997
57 Look at the Lippo Co. earnings release. Lippo drug delivery appears to be catcBill Tomko-2/6/1997
56 Nice find. I will see your article and raise. I'm not doing my research iBill Tomko-2/5/1997
55 Miljenko, First, thank you for a brilliant piece of investigation and analysisWWS-2/4/1997
54 PATENT LITIGATION, Part I Patentbility-claims validity! Before I wrote any of Miljenko Zuanic-2/4/1997
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News